Linked Life Data

18668307

Source:http://linkedlifedata.com/resource/pubmed/id/18668307

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-9-9
pubmed:abstractText
Gemtuzumab Ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53). GO is currently approved in monotherapy for the treatment of CD33+ AML patients in first relapse, showing a 26% overall response rate and a median disease-free-survival of 5.2 months for responders (Larson et al. [2] Cancer 2005;104:1442-52). CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients. Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70). In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient. Here we report the case of a 30-year-old man with a refractory CD33+ ALL who received a salvage regimen combining chemotherapy + GO and achieved a transient CR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0925-5710
pubmed:author
pubmed:issnType
Print
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
209-11
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18668307-Adult, pubmed-meshheading:18668307-Aminoglycosides, pubmed-meshheading:18668307-Antibodies, Monoclonal, pubmed-meshheading:18668307-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18668307-Antigens, CD, pubmed-meshheading:18668307-Antigens, Differentiation, Myelomonocytic, pubmed-meshheading:18668307-Antineoplastic Agents, pubmed-meshheading:18668307-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18668307-Combined Modality Therapy, pubmed-meshheading:18668307-Fatal Outcome, pubmed-meshheading:18668307-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:18668307-Humans, pubmed-meshheading:18668307-Male, pubmed-meshheading:18668307-Philadelphia Chromosome, pubmed-meshheading:18668307-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:18668307-Remission Induction
pubmed:year
2008
pubmed:articleTitle
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
pubmed:affiliation
Department of Hematology, Centre Hospitalier Universitaire, Nantes, France. patrice.chevallier@chu-nantes.fr
pubmed:publicationType
Journal Article, Case Reports